AMGN – Amgen Inc.
Amgen Inc.AMGN
$280.84Name : Amgen Inc.
Sector : Healthcare
Industry: Drug Manufacturers - General
Mark. Cap: $150,868,656,128.00
EPSttm : 7.55
Amgen Inc.
$280.84
0.36%$1.00Float Short %
2.62
Margin Of Safety %
30
Put/Call OI Ratio
0.86001387631266
EPS Next Q Diff
EPS Last/This Y
13
EPS This/Next Y
0.9
Price
280.84
Target Price
311.23
Analyst Recom
2.39
Performance Q
1.97
Relative Volume
0.62
Beta
0.51
Ticker: AMGN
of 1
| Date | Symbol | Last | P/C OI | P/C Vol | Total OI |
|---|---|---|---|---|---|
| 2025-03-27 | AMGN | 305.7 | 0.84 | 3.51 | 171229 |
| 2025-03-28 | AMGN | 306.95 | 0.87 | 2.59 | 174489 |
| 2025-03-31 | AMGN | 310.47 | 0.88 | 0.77 | 175154 |
| 2025-04-01 | AMGN | 306.41 | 0.89 | 0.88 | 179318 |
| 2025-04-02 | AMGN | 305.62 | 0.91 | 1.01 | 184041 |
| 2025-04-03 | AMGN | 310.04 | 0.91 | 0.52 | 186128 |
| 2025-04-04 | AMGN | 294.64 | 0.91 | 2.81 | 187488 |
| 2025-04-07 | AMGN | 289.61 | 0.91 | 2.49 | 185965 |
| 2025-04-08 | AMGN | 279.9 | 0.91 | 2.38 | 188495 |
| 2025-04-09 | AMGN | 290.75 | 0.93 | 1.33 | 193088 |
| 2025-04-10 | AMGN | 281.4 | 0.91 | 1.23 | 197780 |
| 2025-04-11 | AMGN | 285.85 | 0.91 | 0.77 | 201834 |
| 2025-04-14 | AMGN | 293.89 | 0.90 | 0.55 | 195919 |
| 2025-04-15 | AMGN | 295.28 | 0.90 | 1.51 | 196557 |
| 2025-04-16 | AMGN | 282.69 | 0.91 | 2.16 | 198562 |
| 2025-04-17 | AMGN | 277.27 | 0.88 | 0.56 | 197918 |
| 2025-04-18 | AMGN | 277.29 | 0.88 | 0.53 | 197918 |
| 2025-04-21 | AMGN | 273.67 | 0.91 | 0.90 | 153526 |
| 2025-04-22 | AMGN | 278.23 | 0.89 | 0.24 | 154094 |
| 2025-04-23 | AMGN | 277.86 | 0.87 | 0.45 | 156041 |
| 2025-04-24 | AMGN | 279.7 | 0.86 | 1.69 | 157770 |
| 2025-04-25 | AMGN | 280.84 | 0.86001387631266 | 1.4893088015912 | 158170 |
| Date | Symbol | Last | P/C OI | P/C Vol | Total OI |
Current Page1 of 1
of 1
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
|---|---|---|---|---|---|
| 2025-03-27 | AMGN | 305.78 | 7.9 | 7774.7 | 20.64 |
| 2025-03-28 | AMGN | 306.95 | 7.9 | 7818.4 | 20.64 |
| 2025-03-31 | AMGN | 311.39 | 7.9 | 7946.0 | 20.64 |
| 2025-04-01 | AMGN | 306.92 | 7.9 | 7592.7 | 20.64 |
| 2025-04-02 | AMGN | 305.70 | 7.9 | 7724.1 | 20.64 |
| 2025-04-03 | AMGN | 309.93 | 7.9 | 7938.2 | 20.64 |
| 2025-04-04 | AMGN | 294.40 | 7.9 | 7171.0 | 20.64 |
| 2025-04-07 | AMGN | 289.37 | 8.1 | 7568.9 | 20.65 |
| 2025-04-08 | AMGN | 280.26 | 8.1 | 7385.7 | 20.65 |
| 2025-04-09 | AMGN | 291.09 | 8.1 | 8226.9 | 20.65 |
| 2025-04-10 | AMGN | 281.32 | 8.4 | 7373.2 | 20.65 |
| 2025-04-11 | AMGN | 285.94 | 8.4 | 7961.7 | 20.65 |
| 2025-04-14 | AMGN | 293.92 | 8.4 | 8100.4 | 20.65 |
| 2025-04-15 | AMGN | 295.30 | 8.2 | 7827.9 | 20.62 |
| 2025-04-16 | AMGN | 282.74 | 7.4 | 7265.0 | 20.62 |
| 2025-04-17 | AMGN | 277.29 | 7.5 | 7496.4 | 20.62 |
| 2025-04-18 | AMGN | 277.29 | 7.5 | 7718.9 | 20.62 |
| 2025-04-21 | AMGN | 273.60 | 7.7 | 7563.2 | 20.62 |
| 2025-04-22 | AMGN | 278.40 | 7.7 | 7920.2 | 20.62 |
| 2025-04-23 | AMGN | 277.90 | 7.7 | 7697.9 | 20.62 |
| 2025-04-24 | AMGN | 279.70 | 7.7 | 7794.8 | 20.62 |
| 2025-04-25 | AMGN | 280.84 | 7.7 | 7760.8 | 20.62 |
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
Current Page1 of 1
of 1
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
|---|---|---|---|---|
| 2025-03-27 | AMGN | -6.09 | 1.42 | 2.81 |
| 2025-03-28 | AMGN | -6.09 | 1.42 | 2.81 |
| 2025-03-31 | AMGN | -6.09 | 1.20 | 2.81 |
| 2025-04-01 | AMGN | -6.09 | 1.20 | 2.81 |
| 2025-04-02 | AMGN | -6.09 | 1.20 | 2.81 |
| 2025-04-03 | AMGN | -6.09 | 1.20 | 2.81 |
| 2025-04-04 | AMGN | -6.09 | 1.20 | 2.81 |
| 2025-04-07 | AMGN | -6.09 | 1.20 | 2.81 |
| 2025-04-08 | AMGN | -6.09 | 1.20 | 2.81 |
| 2025-04-09 | AMGN | -6.09 | 1.20 | 2.81 |
| 2025-04-10 | AMGN | -6.09 | 1.20 | 2.63 |
| 2025-04-11 | AMGN | -6.09 | 1.20 | 2.63 |
| 2025-04-14 | AMGN | -6.09 | 1.20 | 2.62 |
| 2025-04-15 | AMGN | -6.09 | 1.20 | 2.62 |
| 2025-04-16 | AMGN | -6.08 | 1.20 | 2.62 |
| 2025-04-17 | AMGN | -6.08 | 1.20 | 2.62 |
| 2025-04-18 | AMGN | -6.08 | 1.20 | 2.62 |
| 2025-04-21 | AMGN | -6.08 | 0.80 | 2.62 |
| 2025-04-22 | AMGN | -6.08 | 0.80 | 2.62 |
| 2025-04-23 | AMGN | -6.08 | 0.80 | 2.62 |
| 2025-04-24 | AMGN | -6.08 | 0.80 | 2.62 |
| 2025-04-25 | AMGN | -6.08 | 0.80 | 2.62 |
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
Current Page1 of 1
Last Quarter Act. EPS
5.31
Avg. EPS Est. Current Quarter
4.27
Avg. EPS Est. Next Quarter
5.31
Insider Transactions
-6.08
Institutional Transactions
0.8
Beta
0.51
Average Sales Estimate Current Quarter
8053
Average Sales Estimate Next Quarter
8836
Fair Value
365.06
Quality Score
77
Growth Score
88
Sentiment Score
54
Actual DrawDown %
19
Max Drawdown 5-Year %
-24.9
Target Price
311.23
P/E
37.22
Forward P/E
13.06
PEG
8.82
P/S
4.54
P/B
25.66
P/Free Cash Flow
14.53
EPS
7.55
Average EPS Est. Cur. Y
20.62
EPS Next Y. (Est.)
21.52
Target Price Estimates Raised
Target Price Estimates Lowered
Profit Margin
12.31
Relative Volume
0.62
Return on Equity vs Sector %
48.4
Return on Equity vs Industry %
40.3
EPS 1 7Days Diff
EPS 1 30Days Diff
-0.02
EBIT Estimation
7760.8
Amgen Inc.Sector: Healthcare
Industry: Drug Manufacturers - General
Employees: 28000
Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel for the treatment of rheumatoid arthritis, plaque psoriasis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout. It also markets other products, including Neulasta, MVASI, AMJEVITA/AMGEVITA, TEZSPIRE, Parsabiv, Aimovig, LUMAKRAS/LUMYKRAS, EPOGEN, KANJINTI, TAVNEOS, RAVICTI, UPLIZNA and PROCYSBI. The company serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors, as well as direct-to-consumer channels. The company has collaboration agreements with AstraZeneca plc for the development and commercialization of TEZSPIRE; Novartis Pharma AG to develop and commercialize Aimovig; UCB for the development and commercialization of EVENITY; Kyowa Kirin Co., Ltd. for rocatinlimab development and commercialization; and BeiGene, Ltd. for oncology products expansion and development. Amgen Inc. was incorporated in 1980 and is headquartered in Thousand Oaks, California.
stock quote shares AMGN – Amgen Inc. Stock Price stock today
news today AMGN – Amgen Inc. stock forecast ,stock prediction 2023 2024 2025
marketwatch AMGN – Amgen Inc. yahoo finance google finance
stock history AMGN – Amgen Inc. invest stock market
stock prices AMGN premarket after hours
ticker AMGN fair value insiders trading